Rolofylline
 |
|
| Systematic (IUPAC) name | |
|---|---|
|
8-(Hexahydro-2,5-methanopentalen-3a(1H)-yl)-3,7-dihydro-1,3-dipropyl-1H-purine-2,6-dione
|
|
| Clinical data | |
| Legal status |
|
| Identifiers | |
| CAS Number | 136199-02-5 |
| ATC code | C03BD (WHO) |
| PubChem | CID: 64627 |
| IUPHAR/BPS | 5604 |
| ChemSpider | 58188 |
| UNII | 7805S5HIHX  |
| Chemical data | |
| Formula | C20H28N4O2 |
| Molecular mass | 356.46 g/mol |
Rolofylline (KW-3902) is an experimental diuretic which acts as a selective adenosine A1 receptor antagonist.[1][2] It was discovered at NovaCardia, Inc. which was purchased by Merck & Co., Inc. in 2007.
Development of rolofylline was terminated on September 1, 2009, after the results of a large clinical trial (PROTECT) showed the drug to be no better than placebo for patients with acute heart failure. Participants given rolofylline did show some improvement in shortness of breath, but the drug did not prevent kidney damage or have any significant effect on overall treatment success. Rolofylline was also associated with a higher incidence of seizures and stroke.[3]
References
<templatestyles src="Asbox/styles.css"></templatestyles>
 |
This drug article relating to the cardiovascular system is a stub. You can help Wikipedia by expanding it. |
- Chemical articles having calculated molecular weight overwritten
- Infobox drug articles without a structure image
- Articles without EBI source
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Articles containing unverified chemical infoboxes
- Adenosine receptor antagonists
- Diuretics
- Xanthines
- Cardiovascular system drug stubs
